Article Text

Download PDFPDF
Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review
  1. Amir R Vosoughi1,
  2. Jennifer Ling2,
  3. Kenneth T Tam3,
  4. Jayden Blackwood4,
  5. Jonathan A Micieli5,6,7
  1. 1 Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
  2. 2 Faculty of Medicine, University of British Columbia, Vancouver, Canada
  3. 3 Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Canada
  4. 4 Faculty of Arts and Science, University of Toronto, Toronto, Canada
  5. 5 Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada
  6. 6 Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada
  7. 7 Kensington Vision and Research Centre, Toronto, Canada
  1. Correspondence to Jonathan A. Micieli, Kensington Vision and Research Centre, 501-340 College Street, Toronto, Ontario, Canada; jmicieli{at}kensingtonhealth.org

Abstract

Background/Aims Optic neuritis (ON) is the primary ophthalmic manifestation of myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD), but numerous reports have expanded the visual manifestations of this condition. The goal of this study was to synthesise the extensive literature on this topic to help ophthalmologists understand when testing for MOG-IgG should be considered.

Method A systematic review of the English-language literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searches were conducted using Ovid MEDLINE (from January 1, 1948 to April 1, 2020) and Ovid EMBASE (from January 1, 1947 to April 1, 2020). Inclusion criteria included studies describing non-isolated ON ophthalmic manifestations where cell-based assays were used for the detection of MOG antibodies.

Results Fifty-one articles representing 62 patients with a median age of 32.0 (range 2–65), female gender (51%) and follow-up of 20.0 months (range: 1–240) were included. Twenty-nine patients had non-isolated ON afferent visual manifestations: uveitis, peripheral ulcerative keratitis, acute macular neuroretinopathy, neuroretinitis, venous stasis retinopathy, large preretinal macular haemorrhage, orbital inflammatory syndrome, orbital apex syndrome, optic perineuritis, papilloedema and homonymous visual field defects. Incomplete recovery of ON was associated with a case of Leber’s hereditary optic neuropathy. Efferent ophthalmic manifestations included cranial neuropathies, internuclear ophthalmoplegia, central nystagmus, saccadic intrusions and ocular flutter. Cranial nerve involvement was secondary to enhancement of the cisternal portion or brainstem involvement. All included cases were treated with corticosteroids with 31% of cases requiring additional immunosuppressive therapy.

Conclusions MOGAD has been associated with various afferent and efferent ophthalmic manifestations apart from isolated ON. Awareness of these findings may result in earlier diagnosis and treatment.

  • Optic Nerve
  • Visual pathway
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter Jonathan Micieli @MicieliMD.

  • Contributors AV and JAM gave substantial contributions to conception and design of the work. AV, JL, KT, JB and JAM gave substantial contributions to the acquisition of data and images, to the analysis and interpretation of data for the work and for the final approval of the version to be published. JAM gave substantial contributions to drafting the work and revising it critically for important intellectual content.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Ethics approval Not required as this is a systematic review based on publicly available data.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.